Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00580-25 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Jean-Yves Gillon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland. Hauptthemen laut MEDLINE: Boron Compounds, Trypanocidal Agents, Trypanosomiasis, African. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Aid, Norwegian Agency for Development and Cooperation (Norad), Dutch Ministry of Foreign Affairs.
Abstract (Originalsprache)
Acoziborole is an oxaborole 6-carboxamide active against Trypanosoma brucei gambiense and rhodesiense , the parasites responsible for human African trypanosomiasis. This open-label, phase I study in six healthy male participants evaluated the mass balance, pharmacokinetics, metabolism pathways, and excretion of a single oral 960 mg dose of [ 14 C]-acoziborole. Blood, plasma, and feces were collected for 120 days and urine for 16 days. The excretion balance and systemic exposure of total circulating radioactivity were determined using accelerator mass spectrometry. Metabolism profiling was performed in pools of plasma, urine, and feces. Liquid chromatography coupled with tandem mass spectrometry quantified acoziborole and its metabolite SCYX-3109 in plasma and urine. By Day 60, 87.3% of the total radioactivity had been recovered (10.9% and 74.2% of the total dose in urine and in feces, respectively), with an excretion increment of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
- Quotient Sciences, Nottingham, United Kingdom.
- SGS Belgium S.A., Wavre, Belgium.
- TNO, Leiden, the Netherlands.
- PhinC Development, Massy, France.
- Sanofi R&D, Pharmacokinetics, Dynamics and Metabolism, Montpellier, France.
ORCID-Profile: Jean-Yves Gillon, François Simon, Delphine Launay, Lotte van Andel, Antoine Tarral
Förderung
- UK Aid
- Norwegian Agency for Development and Cooperation (Norad)
- Dutch Ministry of Foreign Affairs
- Federal Ministry of Education and Research
- Swiss Agency for Development and Cooperation
- Médecins Sans Frontières
- Gates Foundation
Zitieren
APA
Gillon, J. Y., Simon, F., Sidhu, S., Louis, M., Launay, D., Wauthier, V., Pelay-Gimeno, M., Andel, L., Loyau, S., Rembry, S., Weinling, E., & Tarral, A. (2025). Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00580-25
Vancouver
Gillon JY, Simon F, Sidhu S, Louis M, Launay D, Wauthier V, et al. Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00580-25
BibTeX
@article{Gillon2025,
author = {Gillon, Jean-Yves and Simon, François and Sidhu, Sharan and Louis, Mathieu and Launay, Delphine and Wauthier, Valérie and Pelay-Gimeno, Marta and Andel, Lotte van and Loyau, Sabrina and Rembry, Sandra and Weinling, Estelle and Tarral, Antoine},
title = {Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00580-25}
}
EUVIMED